Comparing to CDK4/6 inhibitors combine with fulvestrant as the secondary line therapy, therapeutic effects of mVNR combined with one anti-hormonal therapy are not inferior to published data, mVNR also has fewer side effects, especially leukopenia, and the price is less expensive than CDK4/6 inhibitor/fulvestrant combination. Here, CDK4 is linked to Decreased total leukocyte count.